RT Journal Article
SR Electronic
T1 Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4775
OP 4779
DO 10.21873/anticanres.13661
VO 39
IS 9
A1 TASUKU KIYUNA
A1 YASUNORI TOME
A1 KENTARO MIYAKE
A1 TAKASHI MURAKAMI
A1 HIROMICHI OSHIRO
A1 KENTARO IGARASHI
A1 KEI KAWAGUCHI
A1 JOHN HSU
A1 MANISH SINGH
A1 YUNFENG LI
A1 SCOTT NELSON
A1 MICHAEL BOUVET
A1 SHREE RAM SINGH
A1 FUMINORI KANAYA
A1 ROBERT M. HOFFMAN
YR 2019
UL http://ar.iiarjournals.org/content/39/9/4775.abstract
AB Background: Osteosarcoma is a recalcitrant disease treated with surgery and intensive chemotherapy as standard. The 5-year survival rate of patients with relapsed and lung metastatic osteosarcoma is as low as 20%. Materials and Methods: A 16-year-old patient developed left distal femoral high-grade osteosarcoma and underwent cisplatinum-based neoadjuvant chemotherapy and surgery. From the resected tumor, a patient-derived orthotopic xenograft (PDOX) model was established in the femur of nude mice. PDOX models were randomized into the following groups: untreated control, or treatment with doxorubicin (3 mg/kg, i.p., weekly for 14 days), sunitinib (40 mg/kg, oral gavage, daily for 14 days), pazopanib (100 mg/kg, oral gavage, daily for 14 days), temozolomide(25 mg/kg, oral gavage, daily for 14 days), and eribulin (1.5 mg/kg, i.p., daily for 14 days). Tumor volume and body weight were monitored twice a week. Results: The osteosarcoma PDOX was resistant to doxorubicin, sunitinib, and pazopanib. In contrast, eribulin and temozolomide arrested tumor growth. Conclusion: This study demonstrated the utility of the PDOX model in allowing effective from non-effective drugs to be distinguished in a model in which the tumor was growing on the organ corresponding to that of the patient.